Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive AgingRioghna R. Pittock, Maria Vassilaki, Jeremiah A. Aakre et al.|Neurology|2023Cited by 138
Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosisVijay K. Ramanan, Prashanthi Vemuri, Robel K Gebre et al.|Brain|2023Cited by 24
Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease EndophenotypesNathaniel B. Gunter, Clifford R. Jack, Val J. Lowe et al.|Neurology Genetics|2024Cited by 16
Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?Robel K Gebre, Prashanthi Vemuri, Jonathan Graff‐Radford et al.|Brain Communications|2024Cited by 6
Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive AgingMaria Vassilaki, Jonathan Graff‐Radford, Rioghna R. Pittock et al.|Neurology|2024Cited by 1